𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Association of EGFR Gene Amplification and CDKN2 (p16/MTS1) Gene Deletion in Glioblastoma Multiforme

✍ Scribed by Yutaka Hayashi; Keisuke Ueki; Andreas Waha; Otmar D. Wiestler; David N. Louis; Andreas von Deimlina

Book ID
111403736
Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
424 KB
Volume
7
Category
Article
ISSN
1015-6305

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Loss of heterozygosity on chromosome 9 a
Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers
✍ FranΓ§oise Muzeau; Jean FranΓ§ois FlΓ©jou; Gilles Thomas; Richard Hamelin πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 French βš– 131 KB πŸ‘ 1 views

Loss of heterozygosity on chromosome 9 has been reported in a variety of human cancers. The cyclin-dependent kinase inhibitor p16 gene, mapped on chromosome 9p21, is presumed to be the tumor-suppressor gene localized in this chromosome. The aim of our study was to determine, in 26 Barrett's adenocar

Frequency of mutation and deletion of th
Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population
✍ K Biden; J Young; R Buttenshaw; J Searle; G Cooksley; D B Xu; B Leggett πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 476 KB

The tumor suppressor gene CDKN2A (MTS1/p16), located on chromosome 9p21, is inactivated in a variety of tumors including melanomas and tumors of the biliary tract, pancreas, and stomach. The aim of the present study was to determine whether this gene is inactivated in hepatocellular carcinoma (HCC).

Deletional, mutational, and methylation
Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer
✍ David F. Jarrard; G. Steven Bova; Charles M. Ewing; Sokhom S. Pin; Son H. Nguyen πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 98 KB πŸ‘ 1 views

The tumor suppressor gene CDKN2 (p16/MTS1) resides on chromosome 9p21 and encodes a 16 kDa inhibitor of the cyclin-dependent kinases. Inactivation of CDKN2 by homozygous deletion, point mutation, and recently described aberrant methylation in the 5' promoter region may increase progression through t